Pericytoma With t(7;12) and ACTB-GLI1 Fusion
Authors:
- 17 September 2019
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 43 (12) , 1682-1692
Abstract
The entity “pericytoma with t(7;12)” was described as a rare, distinct perivascular myoid neoplasm provisionally classified within the family of myopericytic tumors that demonstrates t(7;12)(p22;q13) translocation with resultant ACTB-GLI1 fusion and biologically was felt to behave in an indolent fashion. However, a recent study showed that tumors with this and similar translocations may have variable morphology and immunohistochemical phenotype with inconsistent myopericytic characteristics and a propensity for metastasis, raising questions regarding the most appropriate classification of these neoplasms. Herein, we report 3 additional patients with tumors harboring t(7;12) and ACTB-GLI1 fusion. The tumors arose in adults and involved the proximal tibia and adjacent soft tissues, scapula and adjacent soft tissues, and ovary. All tumors were composed of round-to-ovoid cells with a richly vascularized stroma with many small, delicate, branching blood vessels, where the neoplastic cells were frequently arranged in a perivascular distribution. Both tumors involving bone showed histologic features of malignancy. By immunohistochemistry, all tested tumors were at least focally positive for smooth muscle actin (3/3) and CD99 (patchy) (2/2), with variable staining for muscle-specific actin (2/3), S100 protein (1/3), epithelial membrane antigen (2/3), and pan-keratin (1/3); all were negative for desmin and WT1 (0/3). The 2 patients with bone tumors developed metastases (27 and 84 mo after diagnosis). Whether these tumors are best classified as malignant myopericytoma variants or an emerging translocation-associated sarcoma of uncertain differentiation remains to be fully clarified; however, our study further documents the potential for these tumors to behave in an aggressive fashion, sometimes over a prolonged clinical course.Keywords
This publication has 25 references indexed in Scilit:
- Clinicopathologic Diversity of Undifferentiated Sarcoma With BCOR-CCNB3 FusionAmerican Journal of Surgical Pathology, 2017
- Gastroblastoma harbors a recurrent somatic MALAT1–GLI1 fusion geneLaboratory Investigation, 2017
- Notch 2 signaling contributes to cell growth, anti-apoptosis and metastasis in laryngeal squamous cell carcinomaMolecular Medicine Reports, 2016
- Recurrent MALAT1–GLI1 oncogenic fusion and GLI1 up‐regulation define a subset of plexiform fibromyxomaThe Journal of Pathology, 2016
- NOTCH pathway inactivation promotes bladder cancer progressionJournal of Clinical Investigation, 2015
- Therapeutic modulation of Notch signalling — are we there yet?Nature Reviews Drug Discovery, 2014
- Landscape of somatic mutations and clonal evolution in mantle cell lymphomaProceedings of the National Academy of Sciences, 2013
- JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted TherapiesGenes & Cancer, 2010
- NOTCH2 Mutations Cause Alagille Syndrome, a Heterogeneous Disorder of the Notch Signaling PathwayThe American Journal of Human Genetics, 2006
- Hemangiopericytoma of the tongue in a 12-year-old child: Ultrastructural and cytogenetic observationsHuman Pathology, 1994